Key result
Prescriptions of metformin (OR 0.49) and SGLT2 inhibitors (OR 0.52) were independently associated with lower rates of cardiovascular death or unplanned HF hospitalization in diabetic HFrEF patients.
Why the study?
The impact of different prescription patterns of diabetes medications on clinical outcomes in patients with heart failure with reduced ejection fraction was evaluated.
Does the prescription of specific diabetes medications like metformin or SGLT2 inhibitors reduce cardiovascular death or unplanned HF hospitalization in diabetic patients with HFrEF?
Cohort (n=381)
No
Does the prescription of specific diabetes medications like metformin or SGLT2 inhibitors reduce cardiovascular death or unplanned HF hospitalization in diabetic patients with HFrEF?
Effect estimate: OR 0.49 (metformin), OR 0.52 (SGLT2i) (95% CI 0.27-0.51 (metformin), 0.28-0.98 (SGLT2i))
p-value: p=<0.001 (metformin), 0.042 (SGLT2i)
In diabetic patients with HFrEF, prescriptions of metformin and SGLT2 inhibitors were associated with significantly lower rates of cardiovascular death or unplanned heart failure hospitalization.
No takes yet. Share an insight, caveat, or question.
Should not yet change prescribing in diabetic HFrEF; leaves open causality and warrants dedicated RCTs.
Chang et al. (2020) conducted a cohort in Diabetic patients with HFrEF (n=381). Metformin and SGLT2 inhibitors vs. Other diabetes medications or non-use was evaluated on Cardiovascular death or first unplanned HF hospitalization (OR 0.49 (metformin), OR 0.52 (SGLT2i), 95% CI 0.27-0.51 (metformin), 0.28-0.98 (SGLT2i), p=<0.001 (metformin), 0.042 (SGLT2i)). Prescriptions of metformin (OR 0.49) and SGLT2 inhibitors (OR 0.52) were independently associated with lower rates of cardiovascular death or unplanned HF hospitalization in diabetic HFrEF patients.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: